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Imidazo[12-a]pyridinesAbstract Molecular modeling studies were carried out on a series of benzimidazole and imidazo-
[1,2-a]pyridines as Plk1 inhibitors. Based on the pharmacophore model, we obtained a ﬁve-featured
hypothesis AADRR, with two hydrogen bond acceptors, one hydrogen bond donor and two
aromatic rings. An atom-based 3D-QSAR model was predicted for 36 training set (R2 = 0.9475,
SD = 0.1927, F= 99.3) and nine test set (Q2 = 0.6519, RMSE = 0.4044, Pearson R= 0.834)
compounds using a pharmacophore-based alignment. From these results, AADRR pharmacophore
feature was chosen as the best common pharmacophore hypothesis, whereas the atom-based 3D-
QSAR results explain the importance of hydrophobic and electron-withdrawing features for the
most active compound 32. The dataset molecules were docked into the active site of Plk1, which
shows acceptable hydrogen bond interactions with residues Cys133, Asp194, Glu131, Lys82 and
Glu140 and also shows further hydrogen bond interactions with hydrophobic residues Cys67,
Leu59 and Arg136. These results can be helpful for further design of novel Plk1 inhibitors.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polo-like kinases (Plks) are a family of serine/threonine kinases
critical for all stages of cell cycle progression, speciﬁcally mito-
sis [1]. Of the different human Plks identiﬁed so far viz. Plk 1
(Plk), Plk2 (Snk), Plk3 (Fnk/Prk), Plk4 (Sak) and Plk5, Plk 5
may not be involved in cell cycle progression, probably due
S312 R. Chekkara et al.to the lack of the kinase domain [2,3,4]. Typically, all Plks
contain an N-terminal catalytic kinase domain which is
responsible for enzyme activation and ATP-binding and a
C-terminal region that consists of one or two polo box domains
(PBDs) involved in phosphopeptide binding. Plk1, the best
characterized member of the Plk family [5,6] regulates several
key steps in the pathway of cells through G2/M transition, cen-
trosome maturation, early embryonic development, DNA rep-
lication, kinetochore assembly, bipolar spindle formation and
cytokinesis [7,8,9,10,11,12,14,15]. All these Plk1 activities are
associated with its subcellular localization. In interphase (G1,
S, G2), Plk1 is involved in DNA replication and centrosome
maturation [13,14], in prophase to mitotic entry [15,16], in pro-
metaphase and metaphase, Plk1 might be involved in spindle
assembly/formation and at telephase, it acts as a key regulator
of cytokinesis [17]. Hence, downregulation of Plk1 activity
promotes cell cycle arrest and apoptosis [18,19].
Over expression of Plk1 is observed in a broad spectrum of
cancer types [20,21,22,23,24,25], and its expression often corre-
lates with the prognosis of tumor patients. A wide range of
natural and synthetic drugs, nearly 20–30 molecules are pres-Table 1 Chemical structures of the training and test set molecules
S
N
N
O
N
R1
Compound R1 R
2 R3
1 H H CF
2 H Me(R) CH
3 H Me Cl
4 H Me(R) Cl
5 CH2OH Me(R) Cl
6 CH2OH Me Cl
7 H Me(R) Cl
8 H Me(R) Cl
9 H Me(R) Cl
10 H Me(R) Cl
11 H Me(R) Cl
12 H Me(R) Cl
13 H Me(R) Cl
14 H Me(R) Cl
15 H Me(R) Cl
16 H Me(R) Cl
17 H Me(R) Cl
18 H Me(R) CFent in clinical and preclinical stage development [26]. Depend-
ing on the oncogenic transformation potential of the enzyme,
small molecular inhibition of Plk1 enzymatic activity by block-
ing its catalytic domain became a momentous feature in cancer
therapy [27,28,29,30].
The aim of this study is to generate a 3D pharmacophore
model, an atom based 3D-QSAR and molecular docking
studies of known Plk1 inhibitors, to know the molecular
mechanisms and structural requirements signiﬁcantly to the
Plk1 inhibition and for further molecular design of potent
novel inhibitors of Plk1. A Pharmacophore model was
generated, which illustrates the importance of speciﬁc struc-
tural features, like the nature of atoms, hydrophobicity, the
functional groups and aromatic features of molecules tar-
geted for a particular enzyme [31,32]. An atom-based 3D-
QSAR model was also developed for understanding the
structure–activity relationship of a set of molecules using
PHASE [33]. The binding mode and the intermolecular
interactions between ligands and the Plk1 enzyme were
examined by performing LigandFit module of Discovery
Studio 2.5.1–18.
O
R2 R3
R4
R4
3 H
2OH H
5-CH2OH
4-CH2OH
H
H
4-(i-Propylamino)methyl
4-(c-Propylamino)methyl
4-(c-Pentylamino)methyl
4-(2-Hydroxyethylamino)methyl
4-(3-Hydroxypropylamino)methyl
4-(1-Hydroxy-2-methylpropan-2-ylamino)methyl
4-(4-Fluoropiperidin-1-yl)methyl
4-(4-Methylpiperazin-1-yl)methyl
4-(4-Hydroxypiperidin-1-yl)methyl
SN
O
O
*
4-(tert-butylamino)methyl
2H 4-(tert-butylamino)methyl
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2.1. Dataset
The dataset of 45 benzimidazole and imidazo[1,2-a] pyridine
derivatives having Plk1 inhibitory activity was used for
3D-QSAR study as shown in Tables 1 and 2 [34–38]. The
inhibitory concentration (IC50) of the Plk1 inhibitors was
converted into pIC50 (pIC50 = logIC50). The compounds
in the data set were divided randomly into 80% of training
set and 20% of test set molecules. Thirty-six molecules of the
training test were used for the generation of pharmacophoreTable 2 Chemical structures of the training and test set molecules
N
S
X
N
R3
O
Y
Compound R1 R
2 X
19 OMe OMe CH
20 H H CH
21 OMe OMe N
22 OMe OMe N
23 OMe OMe N
24 OMe OMe N
25 OMe OMe N
26 OMe OMe N
27 2-Methoxyethoxy 2-Methoxyethoxy N
28 OMe OMe N
29 OMe OMe N
30 OMe OMe N
31 OMe OMe N
32 Phenyl H CH
33 H Phenyl CH
34 H 2-Chloropyridin-4-yl CH
35 2-(Piperazin-1-yl)
pyridin-4-yl
H CH
36 H Piperidin-4-yloxy N
37 H Cyclohexyloxy N
38 H 2-Morpholinoethoxy N
39 H 3-Morpholinopropoxy N
40 H 3-(Dimethylamino)propoxy N
41 H 3-(4-Methylpiperazin-1-yl)propoxy N
42 OMe 3-(4-Methylpiperazin-1-yl)propoxy N
43 H (4-Methylpiperazin-1-yl)methyl N
44 H (4-Methylpiperazin-1-yl)methyl N
45* OMe OMe CH
* Reference compound GW843682X.models, nine molecules of the test set for validation of the
proposed models and for prediction of the activity.
2.2. Ligand preparation
LigPrep module (v2.3 Schro¨dinger 2009) [39], was used for
hydrogen addition, to convert the 2D structures to 3D and
for energy minimization of ligands using OPLS-2005 as a
force ﬁeld. Tautomeric forms were generated using Macro-
Model method (v9.7, Schro¨dinger 2009) [40] after discarding
the current conformers. Mixed MCMM/LMOD Search
Method was used for conformer generation with OPLS-19–45.
R2
R1
Y R3
NH2 1(S)-(2-chlorophenyl)ethoxy
NH2 2-(Triﬂuoromethyl)benzyloxy
OH 3,5-Dichlorophenyl
OH (3-Bromophenyl)
OH 3-(Triﬂuoromethyl)phenyl
OH 3-Chloro-4-(triﬂuoromethyl)phenyl
OH 1-Methyl-1H-indol-5-yl
OH 3,4-Diﬂuorophenyl
OH Phenyl
OH 3-(Hydroxymethyl)phenyl
OH 2,3-Dihydrobenzo[b][1,4]dioxin-6-yl
OH 4-Vinylphenyl
*
N
N
S
O
3-Chlorophenyl
NH2 1(R)-(2-(triﬂuoromethyl)phenyl)ethoxy
NH2 1(R)-(2-(triﬂuoromethyl)phenyl)ethoxy
NH2 1(R)-(2-(triﬂuoromethyl)phenyl)ethoxy
NH2 1(R)-(2-chlorophenyl)ethoxy
NH2 3-Chlorophenyl
NH2 3-Chlorophenyl
NH2 3-Chlorophenyl
NH2 3-Chlorophenyl
NH2 3-Chlorophenyl
NH2 3-Chlorophenyl
NH2 3-Chlorophenyl
NH2 4-(Triﬂuoromethyl)phenyl
NH2 3-(Triﬂuoromethyl)phenyl
NH2 2-(Triﬂuoromethyl)benzyloxy
S314 R. Chekkara et al.2005 force ﬁeld and distance-dependent dielectric solvent
model as MCMM was found to be a better choice for de-
tailed studies of a relatively less number of compounds or
small libraries [41]. For each ligand, a maximum of 2000
conformers were generated ensuing that all the conformers
were minimized up to 500 iterations using TNCG minimiza-
tion. Each minimized conformer was ﬁltered through a rela-
tive energy difference window of 10 kcal/mol and RMSD of
1.00 A˚.
2.3. Pharmacophore studies
To ﬁnd the common pharmacophore hypothesis, the data set
was divided into active and inactive sets in order to simplify
the results of pharmacophore generation and validation.
2.4. Generation of pharmacophore sites
PHASE (v3.1, Schro¨dinger 2009) [42] identiﬁes the spatial
arrangements of functional groups that are common and
essential to the biological activity of a set of high afﬁnity li-
gands. A default six built-in pharmacophore features namely
hydrogen bond acceptor (A), hydrogen bond donor (D),
hydrophobic group (H), negatively charged group (N), posi-
tively charged group (P) and aromatic ring (R) were used to
create pharmacophore sites. The salient pharmacophoric fea-
tures were explained by a set of chemical structure patterns.
The assigned structural patterns are speciﬁed as SMARTS
queries, which allow one of three possible geometries – point,
vector and group, representing the physical characteristics of
the site. Conﬁrming the activity thresholds as 8.1 and 7.0,Table 3 Predicted activity and ﬁtness for the training and test sets
Compound Experimental pIC50 Predicted activity Fitness score C
1 7.6575 7.66 2.56 2
2 7.0555 7.12 2.67 2
3 7.4089 7.5 2.6 2
4b 8.3098 8.02 2.59 2
5c 8.1366 7.71 2.6 2
6a 7.0362 7.69 2.67 2
7 7.5528 7.63 2.55 3
8 7.9208 8.01 2.55 3
9a 7.602 7.64 2.52 3
10 7.6777 7.73 2.54 3
11 7.7212 7.72 2.53 3
12 7.6382 7.64 2.52 3
13a 7.886 7.71 2.51 3
14b 7.7695 7.81 2.51 3
15 7.5686 7.7 2.51 3
16 7.7958 7.85 2.49 3
17 7.3372 7.36 2.53 4
18a 7.6989 7.57 2.59 4
19 7.5228 7.65 2.65 4
20a 7.4559 7.67 2.31 4
21a 7.1804 6.79 1.68 4
22 7.3979 6.82 1.69 4
23 6.8041 6.78 1.68
a Test set compounds.
b Pharmset active compounds.
c Test set and pharmset active compounds.the dataset was divided into ﬁve active and ﬁfteen inactive
compounds that are to be used for pharmacophore modeling
and subsequent scoring.
2.5. Finding common pharmacophore and scoring hypotheses
After comprehensive examination of the pharmacophores,
those pharmacophores that are having identical sets of features
with very similar spatial arrangements were grouped together.
If a given group is retained at least one pharmacophore from
each ligand, that group ride as a common pharmacophore.
A tree-based partitioning algorithm was used for identiﬁcation
of the common pharmacophores, with a maximum tree depth
of ﬁve and the Intersite distance was 2 A˚. The ﬁnal size of the
pharmacophore box, which governs the tolerance on match-
ing, was 1 A˚. Therefore, any pharmacophore in the group
could ultimately become a common pharmacophore hypothe-
sis (CPHs).
2.6. Generation of 3D-QSAR model
PHASE presents atom-based or pharmacophore based 3D-
QSAR models. Due to a common structural framework of
the dataset [43], we have chosen an atom-based 3D-QSAR
model to predict the structure–activity relationship (SAR) of
the molecules. Atom-based 3D-QSAR models were generated
for selected common pharmacophore hypothesis using
36-members of the training set and a grid spacing of 1.0 A˚, a
random seed value of zero and six PLS factors. The developed
3D-QSAR models were validated by predicting activities of
nine test set molecules.of compounds.
ompound Experimental pIC50 Predicted activity Fitness score
4 6.45 6.52 1.58
5 6.4341 6.26 1.68
6a 6.266 6.6 1.69
7 6.0867 6.05 1.73
8a 5.9665 6.68 1.69
9 5.6307 5.74 1.68
0 5.5728 6.24 1.69
1 7.7447 7.83 0.8
2b 8.2218 8.16 3
3 7.7447 7.65 2.62
4 8.3979 8.37 2.67
5 7.2757 7.01 2.73
6 7.0969 7.04 1.74
7 6.1804 6.19 1.74
8 6.7798 6.73 1.01
9 7.6777 7.68 0.87
0 6.7931 6.64 0.27
1 7.4948 7.33 0.35
2 7.7212 7.91 0.97
3 6.1797 6.26 1.43
4 7.2291 7.32 1.43
5b 8.6575 8.56 2.66
Table 4 PLS statistical parameters for the best CPHs.
AADRR AAARR
SD 0.1927 0.1868
R2 0.9475 0.9507
F 99.3 106
P 1.111e-019 3.995e-020
RMSE 0.4044 0.403
Q2 0.6519 0.6542
Pearson R 0.834 0.8175
SD, Standard deviation of the regression; R2, correlation coefﬁ-
cient; F, variance ratio; P, signiﬁcance level of variance ratio;
RMSE, root mean-square error; Q2, predictive coefﬁcient of the test
set; Pearson R, Correlation between the predicted and observed
activities for the test set.
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Molecular docking studies were carried out using LigandFit
module incorporated in Discovery Studio v2.5 [45]. Usually,
the LigandFit docking process includes three stages: (I) Dock-
ing of a ligand into a user deﬁned binding site, (II) In-situ li-
gand minimization, (III) Scoring function calculations for
each pose of ligands. The X-ray crystal structure of the Plk1
protein with coordinating complex Plk1-NMS P937 (PDB
ID: 2YAC) [44] was obtained from the protein data bank
and further modiﬁed for LigandFit docking calculations.Figure 1 The best AADRR hypothesis model. (a) Alignment of the
Alignment of the most active compound 32 (highest ﬁtness value = 3
distances stated in A˚.Receptor-Ligand interactions panel was used for protein prep-
aration; the water molecules and co-crystallized ligands were
removed from the protein and further minimization was per-
formed by applying the CHARMm as force ﬁeld. The docking
energy grid was developed with the co-crystallized ligand
NMS-P937 of 2YAC as the center of the grid, the dataset
and the newly designed molecules were docked in the active
site region of 2YAC using LigandFit of DS to predict the bind-
ing interactions between ligands and Plk1 molecule.
3. Results and discussion
A 3D ligand-based pharmacophore model and an atom-based
3D-QSAR model were generated for a set of benzimidazole
and imidazo[1,2-a]pyridine derivatives, to understand the ef-
fect of spatial arrangement of structural features on Plk1 inhi-
bition. Molecular docking studies were performed to
understand the binding mode of ligands against Plk1 protein.
Predicted activity and ﬁtness score for the training and test
set compounds are shown in Table 3.
The common pharmacophore hypotheses (CPHs) were
generated by dividing the dataset into ﬁve active mole-
cules (pIC50 >= 8.10) and ﬁfteen inactive molecules
(pIC50 <= 7.00) and on consideration of the rest of the
molecule as moderately active. Five featured CPHs were
generated with different combinations of variants. On applying
the scoring function using default values, two best CPHs,most active compounds applied to the AADRR hypothesis. (b)
) applied to the AADRR hypothesis. (c) Hypothesis AADRR, all
S316 R. Chekkara et al.AADRR and AAARR were selected for the atom-based
3D-QSAR model. The 3D-QSAR models were generated in
PHASE using nine test set molecules with six PLS factors. A
summary of statistical data for the two best CPHs is listed in
the Table 4.
The statistical parameters R2, Q2, SD, RMSE, Pearson R
and F were used for evaluation of the two 3D-QSAR models.
AADRR hypothesis has an R2 value of 0.9475 for the training
set and an alluring predictive potential with a Q2 value of
0.6519 for the test set and when compared with the AAARR
hypothesis, AADRR hypothesis possesses a minimum P value
of 1.111e-019 and maximum Pearson R value of 0.834. Thus,
AADRR (two hydrogen bond acceptors (A), one hydrogen
bond donor (D) and two aromatic rings (R) hypothesis was
ﬁnalized as the best model of CPHs.
The alignment generated by the AADRR hypothesis ap-
plied for QSAR model generation is shown in Fig. 1. The cor-
relation between actual and predicted pIC50 of training and
test set compounds is shown in Fig. 2. Angles between the dif-
ferent sites of AADRR hypothesis is shown in Table 5.Figure 2 Scatter plot for the predicted and actual pIC50 va
Table 5 The angles between different sites of AADRR hypothesis.
Site1 Site2 Site3 Angle (A˚)
A2 A1 D4 22.6
A2 A1 R8 12.9
A2 A1 R10 12.5
D4 A1 R8 10.1
D4 A1 R10 35
R8 A1 R10 25.1
A1 A2 D4 112.5
A1 A2 R8 24.8
A1 A2 R10 142.6
D4 A2 R8 88
D4 A2 R10 104.5
R8 A2 R10 164.4
A1 D4 A2 44.9
A1 D4 R8 10.7
A1 D4 R10 81.43.1. QSAR visualization
The contour cubes retrieved from the AADRR hypothesis by
3D-QSAR technique describes the features, which are essential
for the interactions between ligand and Plk1 protein. In a com-
parison of favorable (blue cubes) and unfavorable (red cubes)
regions, a visual image of the contours generated for the most
active compound 32 is shown in Fig. 3. The cubical represen-
tation of different properties such as hydrophobic, electron
withdrawing, hydrogen bond donor and combined effect of
the most active compound 32 with AADRR hypothesis is
shown in Fig. 3a–d.
Visual representation of Fig. 3a shows the presence of blue
cubes at A1, A2 and 1-N of the benzimidazole group and at
the carboxamide group attached to thiophene ring which
shows the favorable regions of electron withdrawing features
of the molecules. It can be suggested that the addition of suit-
able electron withdrawing groups in this favored region will
enhance the Plk1 inhibition activity. Fig. 3b describes that
the addition of hydrophobic groups at R8, R10, attachmentlues of the QSAR model applied to training and test sets.
Site1 Site2 Site3 Angle (A˚)
A2 D4 R8 34.4
A2 D4 R10 36.6
R8 D4 R10 70.8
A1 R8 A2 142.3
A1 R8 D4 159.2
A1 R8 R10 135.4
A2 R8 D4 57.6
A2 R8 R10 9.1
D4 R8 R10 65.1
A1 R10 A2 24.9
A1 R10 D4 63.6
A1 R10 R8 19.5
A2 R10 D4 38.9
A2 R10 R8 6.4
D4 R10 R8 44.2
Figure 3 3D-QSAR visualization of various substituents effects; (a) electron withdrawing feature; (b) hydrophobic features; (c)
hydrogen-bond donor and (d) combined effect.
Table 6 LigandFit dock results of the dataset molecules with 2YAC.
Compound Dock score (kcal/mol) H-bonds Interacting amino acids
1 51.652 2 Cys67, Glu140
2 43.868 2 Cys67, Cys133
3 46.575 4 Asp194, Ser137, Gly180, Lys82
4 49.014 4 Arg57, Lys82, Glu131, Cys133
5 54.15 2 Cys67, Glu140(2)
6 48.479 3 Cys67, Cys133, Asp194
7 40.03 2 Gly62, Lys82 (2)
8 39.748 3 Glu140, Asp194, Asn181
9 42.124 5 Lys61, Leu59, Asp194, Lys62, Cys67
10 60.792 3 Asp194, Asn181, Cys133
11 54.433 3 Arg134, Arg57, Cys67
12 30.55 3 Asp194, Asn181, Cys133
13 27.908 3 Cys67, Phe58, Arg57
14 43.302 2 Asp194, Arg136
15 35.318 2 Lys82, Glu140
16 40.442 2 Arg57, Cys67
17 40.341 3 Asp194 (2), Asp181, Glu140
18 17.709 2 Cys67, Leu59
19 45.102 3 Lys82, Asp194, Cys67
20 56.951 3 Lys82, Glu131, Cys133
21 88.276 3 Val128, Cys133, Asp194
22 93.871 3 Lys82, Asp194, Cys133
23 68.983 3 Gly180, Cys67, Arg136 (2)
24 77.042 3 Asp194, Cys67 (2), Arg136
25 75.873 3 Lys82, Cys67, Cys133
26 88.337 3 Lys82 (2), Lys178 (2), Glu140 (2)
27 94.484 3 Lys82, Asp194, Cys133
28 91.231 3 Asp194, Asn181, Lys82
(continued on next page)
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Table 6 LigandFit dock results of the dataset molecules with 2YAC.
Compound Dock score (kcal/mol) H-bonds Interacting amino acids
29 85.965 3 Lys82 (2), Cys67, Cys133
30 89.95 4 Asp194, Lys82, Cys67, Cys133
31 64.271 4 Lys61, Cys67, Leu59, Arg57
32 45.317 3 Lys82, Cys133, Glu131
33 45.794 2 Cys67, Glu140
34 47.966 2 Cys133, Lys82
35 55.425 2 Lys178, Asp94 (2)
36 77.503 2 Cys67, Lys178, Glu140 (2)
37 57.272 2 Glu140, Cys67
38 61.966 4 Asp194, Lys82, Cys67, Gly62
39 56.895 3 Asp194, Cys67, Arg136
40 69.444 4 Asp194, Cys67, Cys133, Leu59
41 53.823 3 Lys178, Arg136, Arg57
42 63.543 4 Glu140, Cys67, Asp194, Lys178
43 64.406 5 Cys67, Gly62, Gly196, Gly63, Phe195
44 57.018 3 Glu140, Asp194, Arg57
45 54.369 3 Asp194, Cys67, Glu140
Figure 4 The docking results of the most active and least active compound; (a) the binding mode of the most active compound 32
(highest ﬁtness score = 3); (b) the binding mode of the least inactive compound 30.
N
N
S
O
Region favoured with
hydrophobic group
Region f avoured with
electron with drawing groups
Figure 5 Structural requirements for binding and inhibitory
activity of inhibitors.
S318 R. Chekkara et al.of carboxamide group to the thiophene ring, benzimidazole
ring, and phenyl group to the benzimidazole ring, were found
to be acceptable and increases the inhibition of the Plk1 activ-
ity, whereas the addition of hydrophobic groups near to the
ethoxy group attached to thiophene ring decreases the inhibi-
tory potential of the compound represented by the red cubes
specifying the negative potential of hydrophobic groups to that
particular place. Fig. 3c represents that the blue cubes at the
D4 region indicate the positive potential of H-bond donor
groups at that position in molecules. Fig. 3d illustrates the
combined effect of all features expressing the presence of car-
boxamide group attached to thiophene ring and benzimidazole
ring as favorable regions for Plk1 protein binding.
3.2. Docking analysis
Molecular docking simulations were performed using Ligand-
Fit module of DS to understand the binding mode of benz-imidazole and imidazo[1,2-a]pyridine derivatives against
Plk1. In validating the LigandFit dock program, the protein
Table 7 Structure and docking score of the newly designed molecules.
N
N
S
O
R
R1
Comp. R R1 Docking score (kcal/mol) H-bonds Interacting amino acids
D1 –COOH Me 75.335 2 Lys82, Lys67
D2 –OH Me 50.118 3 Cys133, Glu131, Lys82
D3 –NO2 Me 51.193 3 Lys82, Lys67, Lys178
D4 CF3 Me 49.844 2 Cys133, Cys67
D5 OMe Me 59.641 2 Cys67, Glu140
D6 Ac Me 49.945 1 Cys67
D12 –COOH Ph 88.76 2 Cys67, Lys82
D13 –OH Ph 54.438 2 Asp194, Glu140
D14 –NO2 Ph 55.195 3 Lys82, Cys67, Lys178
D15 CF3 Ph 44.548 1 Cys133
D16 OMe Ph 50.425 2 Cys67, Asp194
D17 Ac Ph 54.414 1 Cys133
D7
H
N
Me 54.767 1 Gly180
D8
SH
Me 79.847 2 Asp194, Cys67
D9
NH2
Me 51.689 2 Arg57, Glu131
D10
OH
Me 87.384 2 Cys67, Arg57
D11
O
Me 52.024 1 Arg57
D18
H
N
Ph 55.399 1 Glu140
D19
SH
Ph 66.544 2 Glu131, Arg57
D20
NH2
Ph 56.726 2 Glu131, Arg136
D21
OH
Ph 53.094 2 Arg57, Glu131
D22
O
Ph 57.503 1 Arg57
NMS-P937 72.696 3 Glu140, Lys61, Cys67
Theoretical studies on benzimidazole and imidazo[1,2-a]pyridine derivatives as Plk1 inhibitors S319was redocked with the co-crystallized ligand NMS-P937 of
Plk1 (2YAC) and with a reference molecule GW843682X.
The dataset ligands and the designed molecules were docked
into the active site of Plk1. The docking results of dataset li-
gands are shown in Table 6. The binding mode of the most ac-
tive and least active compounds is shown in Fig. 4.3.3. Binding mode analysis of most active and least active
compounds
Fig. 4a, explains the docking analysis of the compound 32 with
active site of 2YAC. The 3-amino group of the benzimidazole
ring shows interaction with Lys82 (H-bond distance 2.2071 A˚),
S320 R. Chekkara et al.the carboxamide group of C‚O with Cys133 (H-bond dis-
tance 2.1016 A˚) and the amino group with Glu133 (H-bond
distance 1.79103 A˚). Fig. 4b represents the binding analysis of
the least inactive compound 30, wherein the 3-amino group of
benzimidazole ring interacts with Cys133 (H-bond distance
2.1258 A˚), carboxyl group of (C‚O), (C–OH) showing interac-
tion with Lys82 (H-bond distance 1.6731 A˚) and Asp194
(H-bond distance 2.1857 A˚) respectively and amine group of
thiazole ring showing interactions with Cys67 (H-bond distance
2.3242 A˚). As described earlier, even though compound 30
showed good hydrogen interactions and docking score when
compared to compound 32, it became the most inactive because
of the absence of substituted electron withdrawing groups on thi-
azole and benzimidazole rings. Thus the presence of substituted
electron withdrawing groups on thiophene and benzimidazole
rings affords the Plk1 inhibitory potential of compound 32.
After detailed analysis of the 3D-QSAR models and the
docking results, we identiﬁed the structural requirements that
are necessary for molecules in the inhibition of Plk1 activity
(Fig. 5). Further, the molecules were modiﬁed to enhance the
inhibitory activity against Plk1 protein. Hence, we substituted
electron withdrawing groups and hydrophobic features on the
newly designed molecules, which show satisfactory docking re-
sults when compared to the dataset molecules, and the docking
results are shown in Table 7.
4. Conclusions
The main aim of this study is to understand the salient struc-
tural features of selective Plk1 inhibitors, which will be useful
for further design of novel effective Plk1 inhibitors. PHASE
was used for the development of pharmacophore models and
an atom-based 3D-QSAR model developed based on pharma-
cophore-based alignment. Pharmacophore studies reveal that
two hydrogen bond acceptors, one hydrogen bond donor
and two aromatic rings are the essential signiﬁcant features
for ligand binding, analyzed by docking studies where these
features show good interactions with amino acids Cys133,
Asp194, Glu131, Lys82, and Glu140 and also show further
interactions with hydrophobic residues Cys67, Leu59 and
Arg136 in the binding site of Plk1. Visual representation of
the 3D-QSAR model explains the structural activity relation-
ship, the inﬂuence of electron withdrawing, hydrophobic and
H-donor features of molecular structure on Plk1 inhibition.
The newly designed molecules based on these hydrophobic
and electron withdrawing features also show better binding
interactions with the active and hydrophobic residues of the
Plk1 active domain. The combination of these molecular mod-
eling results will provide the information required for better
understanding of structural features necessary for biological
interaction and are expected to be useful for further design
of novel active Plk1 inhibitors.
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